AIL
NBIX icon

AGF Investments LLC’s Neurocrine Biosciences NBIX Stock Holding History

AGF Investments LLC’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		$1.7M Buy
16,003
+5,101
+47% +$518K 0.16% 37
2022
Q2 		$1.06M Buy
10,902
+1,329
+14% +$123K 0.1% 39
2022
Q1 		$897K Buy
+9,573
New +$811K 0.07% 119
2021
Q1 		– Sell
-7,766
Closed -$744K – 478
2020
Q4 		$744K Sell
7,766
-4,505
-37% -$435K 0.09% 203
2020
Q3 		$1.18M Buy
12,271
+2,306
+23% +$267K 0.13% 209
2020
Q2 		$1.22M Buy
9,965
+1,748
+21% +$193K 0.12% 177
2020
Q1 		$711K Buy
8,217
+890
+12% +$87.1K 0.09% 169
2019
Q4 		$788K Buy
7,327
+2,724
+59% +$285K 0.15% 301
2019
Q3 		$415K Buy
+4,603
New +$430K 0.1% 317
2018
Q4 		– Sell
-215
Closed -$27K – 776
2018
Q3 		$27K Sell
215
-149
-41% -$16.9K ﹤0.01% 494
2018
Q2 		$36 Sell
364
-428
-54% -$38.3K ﹤0.01% 495
2018
Q1 		$66K Buy
792
+306
+63% +$25.8K 0.01% 279
2017
Q4 		$38K Buy
+486
New +$33.1K 0.01% 292

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

AGF Investments LLC's NBIX Position: Q3 2022 in Review

AGF Investments LLC increased its Neurocrine Biosciences (NBIX) stake by 47% in Q3 2022, buying an estimated $518K and bringing the position to 16,003 shares worth $1.7M. The position accounts for 0.16% of the portfolio, ranked #37.

AGF Investments LLC first reported a position in NBIX in Q4 2017 and has held it in 13 quarters since. 467 funds tracked by Wall St. Rank hold NBIX as of Q3 2022.

  • AGF Investments LLC held 16,003 shares of Neurocrine Biosciences worth $1.7M as of Q3 2022.
  • AGF Investments LLC bought 5,101 Neurocrine Biosciences shares in Q3 2022, an estimated $518K.
  • Neurocrine Biosciences made up 0.16% of AGF Investments LLC's portfolio in Q3 2022, its #37 holding.
  • AGF Investments LLC first reported a position in Neurocrine Biosciences in Q4 2017 and has held it in 13 quarters since.
  • 467 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2022.

Based on AGF Investments LLC's 13F filing for Q3 2022, filed 10 Nov 2022.